Sanofi wins FDA nod for Wayrilz in bleeding disorder thrombocytopenia

1 day ago 2

The U.S. Food and Drug Administration (FDA) has approved Wayrilz, a Bruton’s tyrosine kinase (BTK) inhibitor developed by Sanofi (NASDAQ:SNY), as a treatment for a bleeding disorder known as immune thrombocytopenia (ITP).
Accordingly, the oral treatment currently under review for ITP